Duke Study Explores Nasal Swab as Early Alzheimer’s Detection Tool Amid Growing Treatment Options

A groundbreaking Duke University study is investigating whether a simple nasal swab could revolutionize the early detection of Alzheimer’s disease, offering hope to millions of Americans who may one day benefit from treatments that can slow—or even prevent—cognitive decline before irreversible damage occurs. Led by Dr. Brad Goldstein, a Duke Health physician-scientist, the research leverages the olfactory system—the neural network responsible for smell—as a potential ‘window to the brain,’ where early pathological changes linked to Alzheimer’s may first manifest. With newly approved Alzheimer’s drugs showing the greatest efficacy when administered in the disease’s earliest stages, the study’s findings could dramatically reshape how the condition is identified and managed.

Why Early Alzheimer’s Detection Matters: New Treatments Demand Earlier Diagnosis

Alzheimer’s disease is the sixth-leading cause of death in the United States, with an estimated 6.7 million Americans aged 65 and older living with the condition in 2025—a number projected to nearly double by 2060, according to the Alzheimer’s Association. While there is currently no cure, the U.S. Food and Drug Administration’s (FDA) approval of disease-modifying therapies such as lecanemab (Leqembi) and donanemab (Kisunla) has shifted the treatment paradigm. These drugs, which target amyloid plaques in the brain, have shown the ability to slow cognitive decline by up to 35% in early-stage patients when administered before severe neuronal damage occurs. However, their effectiveness hinges on early intervention, making timely diagnosis critical. Traditional diagnostic methods—including lumbar punctures, PET scans, and blood tests—often fall short: they are either invasive, costly, or detect biomarkers only after significant brain damage has already taken place.

The Limitations of Current Alzheimer’s Detection Methods

The gold standard for Alzheimer’s diagnosis in living patients remains a lumbar puncture, which extracts cerebrospinal fluid (CSF) to measure amyloid beta and tau proteins. While highly accurate, the procedure carries risks such as headaches, infection, and discomfort, making it unsuitable for widespread screening. Amyloid PET scans, another diagnostic tool, are less invasive but prohibitively expensive, costing upwards of $4,000 per scan and often requiring insurance pre-authorization. Blood-based biomarker tests, such as those measuring phosphorylated tau-217 (p-tau217), are gaining traction but are currently limited to detecting later-stage disease processes. ‘We’re looking at neural and immune tissue directly from the nose, not just markers that have leaked into the blood,’ Goldstein explained. ‘This could capture early changes in the olfactory system before they become systemic or widespread.’

The Science Behind Nasal Swabs and Alzheimer’s Detection

The olfactory mucosa, a tissue lining the upper part of the nasal cavity, contains a unique blend of neural and immune cells that directly connect to the brain via the olfactory bulb. This anatomical proximity makes it a prime candidate for detecting early neurodegenerative changes. In Alzheimer’s disease, abnormal tau and amyloid proteins accumulate in the brain’s olfactory regions long before symptoms like memory loss appear. Goldstein’s team hypothesizes that these pathological proteins may also accumulate in the olfactory mucosa, offering a non-invasive biopsy site. ‘The nose is essentially a gateway to the central nervous system,’ Goldstein said. ‘We can access this tissue with minimal discomfort using a small brush after numbing the area with a spray. It’s a procedure that takes minutes and avoids the risks of more invasive methods.’

How the Study Is Being Conducted: A Closer Look at the Research Process

The Duke-led study, funded in part by a grant from the National Institutes of Health (NIH), involves collecting tissue samples from the olfactory cleft—the narrow passage at the back of the nasal cavity—using a soft, flexible brush under endoscopic guidance. Participants, including both healthy individuals and those with varying degrees of cognitive impairment, undergo the procedure after receiving a topical anesthetic. The samples are then analyzed for the presence of tau and amyloid proteins, as well as inflammatory markers linked to Alzheimer’s pathology. ‘We’re not just looking for proteins,’ Goldstein noted. ‘We’re examining the cellular environment—how immune cells in the nose might respond to early brain changes. This could reveal entirely new biomarkers we haven’t considered before.’ The study is part of the Duke-UNC Alzheimer’s Disease Research Center, established in 2021 to foster collaboration between Duke University and the University of North Carolina at Chapel Hill in tackling the disease.

The Human Impact: Families Share Their Struggles and Hopes

For families like that of Mary Umstead of Durham, North Carolina, the promise of earlier detection offers a glimmer of hope amid heartbreak. Umstead lost her sister, Mariah, to Alzheimer’s in 2023 at the age of 62—a disease that robbed her of her sharp wit, independence, and, eventually, her identity. ‘She was the most wonderful person—warm, kind, and genuinely funny,’ Umstead recalled. ‘We all joke about forgetting names as we age, but her struggles started much earlier. She worked 80-hour weeks trying to keep up, and we had to constantly watch over her to ensure her safety.’ The emotional toll of watching a loved one slip away underscores why Umstead eagerly volunteered for Goldstein’s study. ‘If I can help even one family avoid what we went through, it’s worth it,’ she said. ‘The new medications won’t cure Alzheimer’s, but they can slow its progress. If we can catch it sooner, maybe we can preserve more of who that person is—their humor, their snark, the things that make them them.’

• A nasal swab could offer a non-invasive, cost-effective method to detect Alzheimer’s disease in its earliest stages, potentially before symptoms appear.
• Newly approved Alzheimer’s drugs like lecanemab and donanemab require early intervention, making timely diagnosis critical to slowing cognitive decline.
• The olfactory mucosa in the nose may harbor early pathological changes linked to Alzheimer’s, providing a ‘window to the brain’ for diagnosis.
• Current diagnostic methods, such as lumbar punctures and PET scans, are either invasive, expensive, or detect biomarkers too late for optimal treatment.
• Duke’s study is part of a broader effort to explore how the olfactory system can be leveraged to improve early detection of neurodegenerative diseases.

Broader Implications: Could This Approach Work for Other Neurodegenerative Diseases?

While Goldstein’s research focuses on Alzheimer’s, the findings could have far-reaching implications for other neurodegenerative conditions. Parkinson’s disease, for example, is also strongly associated with olfactory dysfunction—up to 90% of Parkinson’s patients experience smell loss years before motor symptoms emerge. Similarly, studies have shown that the loss of smell can precede cognitive decline in Lewy body dementia and even frontotemporal dementia. ‘There’s a growing body of evidence that the olfactory system is uniquely vulnerable to early pathological changes in multiple neurodegenerative diseases,’ Goldstein said. ‘If our nasal swab approach proves successful for Alzheimer’s, it could pave the way for similar tests for Parkinson’s, ALS, and other conditions where early detection is critical.’ The potential to streamline diagnostics across a spectrum of brain disorders could significantly reduce healthcare costs and improve patient outcomes.

Challenges and Next Steps: What’s Ahead for This Research?

Despite the promise of the nasal swab method, researchers emphasize that it is still in the early stages of development. The current study involves a small cohort of participants, and larger-scale clinical trials will be necessary to validate the technique’s accuracy and reliability. Goldstein’s team is also exploring whether the swab can detect other biomarkers, such as neurofilament light chain (NfL), a protein associated with neuronal damage. ‘We’re at the tip of the iceberg,’ Goldstein cautioned. ‘We need to confirm that the proteins we find in the nasal tissue correlate with what’s happening in the brain. If we can do that, this could become a game-changer.’ In the meantime, the Alzheimer’s Association estimates that nearly 13 million Americans will be living with Alzheimer’s dementia by 2050, with annual costs exceeding $1 trillion. The need for scalable, accessible diagnostic tools has never been more urgent.

‘The difference we could potentially make in preventing disease progression for patients and families would be huge. If we can catch this early enough, we might not just slow the disease—we might stop it in its tracks before it really begins.’ — Dr. Brad Goldstein, Duke Health physician-scientist

How to Support Alzheimer’s Research and Early Detection Efforts

For those interested in contributing to Alzheimer’s research or learning more about early detection, several avenues exist. The Alzheimer’s Association offers resources for clinical trial participation, including studies on new diagnostic tools like the nasal swab method. Duke University’s Alzheimer’s Disease Research Center is actively recruiting participants for Goldstein’s study, with eligibility criteria available on their website. Additionally, organizations such as the BrightFocus Foundation and the Alzheimer’s Drug Discovery Foundation fund innovative research into early biomarkers and treatments. ‘Every dollar donated, every hour volunteered, and every story shared helps move the needle forward,’ Umstead said. ‘This disease doesn’t just affect the person diagnosed—it affects entire families. We all have a role to play in changing its trajectory.’

Key Takeaways: What This Research Means for Patients and Families

• Duke researchers are pioneering a nasal swab test that could detect Alzheimer’s disease earlier by analyzing cells in the olfactory mucosa, offering a non-invasive alternative to current diagnostic methods.
• New Alzheimer’s drugs like lecanemab and donanemab are most effective when administered in the disease’s earliest stages, making timely diagnosis critical for slowing cognitive decline.
• The olfactory system may provide a ‘window to the brain,’ as early pathological changes linked to Alzheimer’s can appear in the nose before symptoms manifest.
• Current diagnostic tools—such as lumbar punctures and PET scans—are either invasive, expensive, or detect biomarkers too late for optimal treatment.
• Larger clinical trials are needed to validate the nasal swab method, but if successful, it could revolutionize Alzheimer’s detection and potentially extend to other neurodegenerative diseases.

Frequently Asked Questions